drugset / Trial / NCT07053319
SGLT2i, Pioglitazone, and Ketone Production in T2D
Phase 1
Recruiting
64 enrolled
The University of Texas Health Science Center at San Antonio
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · collab
RandomizedParallel-groupTriple-blindBasic science
Summary
To examine whether the empagliflozin-induced stimulation of EGP, lipolysis, and ketone production in T2D individuals can be blocked by pioglitazone (which has direct hepatic and adipose tissue effects).
Timeline
- Start
- 2026-05-11
- Primary completion
- 2027-06-01
- Completion
- 2027-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Empagliflozin | Small molecule | 25 mg | — |
| Comparator | Pioglitazone | Small molecule | 30 mg | — |